opc/obesity

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 81 rezilta yo

Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To assess the efficacy and safety of aripiprazole once-monthly 400 mg (AOM 400), an extended-release injectable suspension of aripiprazole, in obese and nonobese patients. METHODS This post hoc analysis of a 38-week randomized, double-blind, active-controlled, noninferiority study

Treatment with aripiprazole and topiramate in an obese subject with borderline personality disorder, obsessive-compulsive symptoms and bulimia nervosa: a case report.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Borderline personality disorder is a chronic mental disorder associated with severe psychosocial impairment and morbidity, greater usage of mental health resources, and a high mortality rate. Although there is no drug with an approved indication for this disorder, pharmacological

Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Olanzapine treatment has been associated with clinically meaningful weight increases, hypertriglyceridemia, insulin resistance, and diabetes mellitus. There are few options for olanzapine responders who fail other antipsychotic agents. Aripiprazole is a potent (high-affinity) partial agonist at D2

A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Major mental disorders are associated with an increased risk for obesity-related cardiovascular mortality, leading to interest in risk-reduction approaches that target weight and risk-related plasma lipids, including use of antipsychotic agents with low metabolic risk. This multicenter,

A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To investigate the feasibility of switching overweight schizophrenic patients to aripiprazole and to assess the impact of 12 months of aripiprazole treatment on weight in routine practice. METHODS This was a non-controlled cohort study in overweight schizophrenic patients. Data were

[The use of aripiprazole in the treatment of obesity associated with the administration of neuroleptics of the second generation in patients with schizophrenia].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To investigate the advisability of using aripiprazole in schizophrenic patients with weight gain associated with treatment with atypical neuroleptics. METHODS We studied 62 patients with schizophrenia in therapeutic remission. In all patients, weight gain was associated with the

Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

First manic episode associated with use of human chorionic gonadotropin for obesity: a case report.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Although highly controversial, the treatment of obesity with exogenous human chorionic gonadotropin (HCG) remains popular in the USA. We report the case of a patient whose first manic episode was associated with the use of HCG for weight loss. METHODS A 32-year-old female patient was

Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Bipolar I disorder (BPD) patients are often overweight or obese, and likely to have metabolic syndrome. Several medications used to treat BPD are associated with increased body weight and/or worsening metabolic parameters. METHODS Metabolic data were analyzed from two efficacy studies of

Weight gain and metabolic screening in young people with early psychosis on long acting injectable antipsychotic medication (aripiprazole vs paliperidone)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Aim: Long-acting injectable (LAI)antipsychotics are often used in psychosis to assist with medication compliance and relapse prevention, although the weight gain and metabolic effects in young people are yet to be examined. This study

Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In 2 identical multicenter, double-blind, placebo-controlled trials, an 8-week prospective treatment phase to ensure inadequate response to standard antidepressants was followed with 6 weeks of aripiprazole (2-20 mg/d) or placebo, plus a standard antidepressant. This pooled analysis involving 737

Aripiprazole cytotoxicity coincides with activation of the unfolded protein response in human hepatic cells

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Schizophrenia is a mental disease that results in decreased life expectancy and wellbeing, by promoting obesity and sedentary lifestyles. Schizophrenia is treated by antipsychotic drugs. While the second generation of antipsychotics (SGA), Olanzapine and Aripiprazole are more effective in treating

[A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The D2 dopamine receptors play a pivotal role in the physiopathology of schizophrenia. Their over-stimulation in the limbic area, resulting from a hyperactivity of the mesolimbic dopaminergic neurones, is linked to positive expressions of the disease, whereas their lack of stimulation in cortical

Weight gain changes in patients with aripiprazole monotherapy compared with aripiprazole-antidepressant polypharmacy in an outpatient sample.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE This study seeks to evaluate the weight gain effect within a community-based population of patients with diagnoses of depression, mood disorder, and schizophrenia receiving aripiprazole over a period of at least 6 months. METHODS The four million members of Kaiser Permanente of Southern

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye